Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q13485

UPID:
SMAD4_HUMAN

ALTERNATIVE NAMES:
Deletion target in pancreatic carcinoma 4; SMAD family member 4

ALTERNATIVE UPACC:
Q13485; A8K405

BACKGROUND:
The protein SMAD4, also known as Mothers against decapentaplegic homolog 4, is integral to the TGF-beta signaling pathway, mediating cellular responses to growth factors. Its role extends to promoting DNA binding and transcriptional activation in response to TGF-beta, showcasing its significance in cellular regulation and development.

THERAPEUTIC SIGNIFICANCE:
Given SMAD4's involvement in critical diseases like Pancreatic cancer and Colorectal cancer, its study offers promising avenues for drug discovery. The protein's function in disease pathogenesis provides a foundation for developing targeted therapies, highlighting the therapeutic potential of SMAD4 research.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.